South San Francisco-based Veracyte entered a multi-year partnership with AstraZeneca 's hematology research and development unit, Acerta Pharma. This is Veracyte's first biopharma partnership since it acquired exclusive diagnostics rights to the NanoString nCounter platform and genomic tests in breast cancer and lymphoma on December 3, 2019. Under the collaboration deal with Acerta, Veracyte will offer genomic information in support of Acerta's oncology development program. Financial details were not disclosed. "We are excited to partner with Acerta Pharma and AstraZeneca, global leaders whose innovative medicines are benefiting millions of patients worldwide," said Bonnie H. Anderson, Veracyte's chairman and chief executive officer.